Combined Access Strategies for Portal Vein Recanalization with Transjugular Intrahepatic Portosystemic Shunt in Pediatric Chronic Portal Vein Thrombosis: A Series of 3 Cases.

J Vasc Interv RadiolJul 23, 2026 (epub)
Case ReportPediatricsGastroenterologyVascular Surgery

Monifa Al Akoum, Hussein Tarhini, Peter Noun et al.

✦ AI-curated · Sources linked

Case in brief

Three pediatric patients aged 11 months to 11 years with chronic portal vein thrombosis underwent successful portal vein recanalization with transjugular intrahepatic portosystemic shunt (PVR-TIPS) using tailored access strategies. All cases achieved technical success, restoring portal venous flow and creating TIPS. Follow-up revealed shunt-related complications in two patients, while one developed a hepatic arterioportal fistula, both of which were successfully managed.

Diagnostic / clinical pearl

PVR-TIPS can be a viable endovascular treatment for pediatric patients with chronic portal vein thrombosis, especially those with complex anatomy, but requires careful imaging follow-up to monitor for complications.

Source

PubMed · PMID 42492773

Published in J Vasc Interv Radiol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.